Here are the Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Efficacy of measles vaccine, efficacy of cbt, dapagliflozin in acute illness, dapagliflozin for heart problems, use of dapagliflozin in heart failure.
Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis
Introduction: Dapagliflozin shows some potential in treating nonalcoholic fatty liver disease complicated with type 2 diabetes, and this meta-analysis aims to explore the efficacy of dapagliflozin vs placebo to treat nonalcoholic fatty liver disease complicated with type 2 diabetes.
Methods: PubMed, EMbase, Web of science, EBSCO and Cochrane library databases have been searched through July 2024, and we included randomized controlled trials (RCTs) assessing the efficacy of dapagliflozin for nonalcoholic fatty liver disease complicated with type 2 diabetes.
Results: Five RCTs and 353 patients were included in the meta-analysis. Overall, compared with control intervention in patients with nonalcoholic fatty liver disease and type 2 diabetes, dapagliflozin treatment was able to significantly decrease ALT (standard mean difference [SMD] = -1.10; 95% confidence interval [CI] = -1.37 to -0.84; P < .00001), AST (MD = -1 .32; 95% CI = -1.76 to -0.88; P < .00001) and HbA1c (SMD = -0.60; 95% CI = -1.02 to -0.17; P = .006), but demonstrated no influence on fasting glucose (SMD = -0.55; 95% CI = -1.10 to 0; P = .05), LDL-C (SMD = -0.19; 95% CI = -0.56 to 0.17; P = .30) or triglyceride (SMD = -0.30; 95% CI = -1.47 to 0.88; P = .62). Conclusions: Dapagliflozin may benefit to treat patients with nonalcoholic fatty liver disease and type 2 diabetes. © 2025 the Author(s). Published by Wolters Kluwer Health, Inc.
Authors : Duan H.; Chen F.
Source : Lippincott Williams and Wilkins
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.1097/MD.0000000000040836 |
| ISSN | 00257974 |
| Volume | 104 |
You can download the article here
If You have any problem, contact us here